This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
7 Feb 2012

GSK to Expand Manufacturing Capacity at Australian Plant

GlaxoSmithKline will invest A$60m to expand its manufacturing and new drug development activities in Australia.

UK-headquartered pharmaceutical firm GlaxoSmithKline will invest A$60m (US$64m) to expand its manufacturing and new drug development activities in Victoria, Australia, creating 58 new jobs by 2017.

 

GSK has had a base in Australia for nearly 130 years and is a significant contributor to the local economy, spending on average more than A$30m a year on r&d in Victoria and exporting more than A$300m a year in pharmaceutical products from the state.

 

GSK’s Boronia site, east of Melbourne, manufactures medicines for migraine, herpes, epilepsy, smoking cessation, hypertension, asthma, pain relief and anti-virals. The site is also the company's largest site globally for the production of sterile and non-sterile liquid products using ‘blow-fill-seal’ (BFS) technology. <

Related News